333 related articles for article (PubMed ID: 32344256)
21. Novel 2-aryl-4-(4'-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors.
Park S; Kadayat TM; Jun KY; Thapa Magar TB; Bist G; Shrestha A; Lee ES; Kwon Y
Eur J Med Chem; 2017 Jan; 125():14-28. PubMed ID: 27643560
[TBL] [Abstract][Full Text] [Related]
22. Bioassays and In Silico Methods in the Identification of Human DNA Topoisomerase IIα Inhibitors.
Bergant K; Janezic M; Perdih A
Curr Med Chem; 2018; 25(28):3286-3318. PubMed ID: 29508675
[TBL] [Abstract][Full Text] [Related]
23. (S)-Erypoegin K, an isoflavone isolated from Erythrina poeppigiana, is a novel inhibitor of topoisomerase IIα: Induction of G2 phase arrest in human gastric cancer cells.
Hikita K; Yamakage Y; Okunaga H; Motoyama Y; Matsuyama H; Matsuoka K; Murata T; Nakayoshi T; Oda A; Kato K; Tanaka H; Asao N; Dan S; Kaneda N
Bioorg Med Chem; 2021 Jan; 30():115904. PubMed ID: 33341500
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
[TBL] [Abstract][Full Text] [Related]
25. Development of β-carboline-benzothiazole hybrids via carboxamide formation as cytotoxic agents: DNA intercalative topoisomerase IIα inhibition and apoptosis induction.
Tokala R; Mahajan S; Kiranmai G; Sigalapalli DK; Sana S; John SE; Nagesh N; Shankaraiah N
Bioorg Chem; 2021 Jan; 106():104481. PubMed ID: 33261848
[TBL] [Abstract][Full Text] [Related]
26. Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.
Bhosle J; Kiakos K; Porter AC; Wu J; Makris A; Hartley JA; Hochhauser D
Mol Cancer Ther; 2013 Dec; 12(12):2897-908. PubMed ID: 24092808
[TBL] [Abstract][Full Text] [Related]
27. Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and IIα dual inhibitors with DNA non-intercalative catalytic activity.
Bist G; Park S; Song C; Thapa Magar TB; Shrestha A; Kwon Y; Lee ES
Eur J Med Chem; 2017 Jun; 133():69-84. PubMed ID: 28384547
[TBL] [Abstract][Full Text] [Related]
28. Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.
Drwal MN; Marinello J; Manzo SG; Wakelin LP; Capranico G; Griffith R
PLoS One; 2014; 9(12):e114904. PubMed ID: 25489853
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
[TBL] [Abstract][Full Text] [Related]
30. Development of 13H-benzo[f]chromeno[4,3-b][1,7]naphthyridines and their salts as potent cytotoxic agents and topoisomerase I/IIα inhibitors.
Arepalli SK; Lee C; Sim S; Lee K; Jo H; Jun KY; Kwon Y; Kang JS; Jung JK; Lee H
Bioorg Med Chem; 2018 Oct; 26(18):5181-5193. PubMed ID: 30253887
[TBL] [Abstract][Full Text] [Related]
31. Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide).
Congdon LM; Pourpak A; Escalante AM; Dorr RT; Landowski TH
Biochem Pharmacol; 2008 Feb; 75(4):883-90. PubMed ID: 18062937
[TBL] [Abstract][Full Text] [Related]
32. R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II.
Zhu H; Huang M; Yang F; Chen Y; Miao ZH; Qian XH; Xu YF; Qin YX; Luo HB; Shen X; Geng MY; Cai YJ; Ding J
Mol Cancer Ther; 2007 Feb; 6(2):484-95. PubMed ID: 17308047
[TBL] [Abstract][Full Text] [Related]
33. Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting ATP hydrolysis of topoisomerase II.
Li Y; Luan Y; Qi X; Li M; Gong L; Xue X; Wu X; Wu Y; Chen M; Xing G; Yao J; Ren J
Toxicol Sci; 2010 Dec; 118(2):435-43. PubMed ID: 20855424
[TBL] [Abstract][Full Text] [Related]
34. DNA damage response (DDR) induced by topoisomerase II poisons requires nuclear function of the small GTPase Rac.
Wartlick F; Bopp A; Henninger C; Fritz G
Biochim Biophys Acta; 2013 Dec; 1833(12):3093-3103. PubMed ID: 23999236
[TBL] [Abstract][Full Text] [Related]
35. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
Kozuki T; Chikamori K; Surleac MD; Micluta MA; Petrescu AJ; Norris EJ; Elson P; Hoeltge GA; Grabowski DR; Porter ACG; Ganapathi RN; Ganapathi MK
Nucleic Acids Res; 2017 Jun; 45(10):5995-6010. PubMed ID: 28472494
[TBL] [Abstract][Full Text] [Related]
36. Combined treatment with temozolomide and methoxyamine: blocking apurininc/pyrimidinic site repair coupled with targeting topoisomerase IIalpha.
Yan L; Bulgar A; Miao Y; Mahajan V; Donze JR; Gerson SL; Liu L
Clin Cancer Res; 2007 Mar; 13(5):1532-9. PubMed ID: 17332299
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, biological evaluation, structure-activity relationship study, and mode of action of 2-phenol-4,6-dichlorophenyl-pyridines.
Shrestha A; Park S; Shin S; Man Kadayat T; Bist G; Katila P; Kwon Y; Lee ES
Bioorg Chem; 2018 Sep; 79():1-18. PubMed ID: 29715635
[TBL] [Abstract][Full Text] [Related]
38. 1,2-Naphthoquinone as a Poison of Human Type II Topoisomerases.
Collins JA; Osheroff N
Chem Res Toxicol; 2021 Apr; 34(4):1082-1090. PubMed ID: 33760604
[TBL] [Abstract][Full Text] [Related]
39. (-)-Xanthatin up-regulation of the GADD45γ tumor suppressor gene in MDA-MB-231 breast cancer cells: role of topoisomerase IIα inhibition and reactive oxygen species.
Takeda S; Noguchi M; Matsuo K; Yamaguchi Y; Kudo T; Nishimura H; Okamoto Y; Amamoto T; Shindo M; Omiecinski CJ; Aramaki H
Toxicology; 2013 Mar; 305():1-9. PubMed ID: 23313378
[TBL] [Abstract][Full Text] [Related]
40. 2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.
Mensah-Osman EJ; Al-Katib AM; Wu HY; Osman NI; Mohammad RM
Mol Cancer Ther; 2002 Dec; 1(14):1321-6. PubMed ID: 12516965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
